David Berman

Biography

David Berman is Senior Vice President and Head of the Oncology Innovative Medicines unit (iMED) at MedImmune. As iMED head, he leads the cross-functional teams responsible for the strategy, growth, and advancement of the oncology portfolio. Dr. Berman sit’s on AstraZeneca’s Cancer Enterprise team working closely with his small-molecule, GMD and GPPS colleagues. Prior to joining MedImmune, Dr. Berman was Vice President and Head of the Immuno-Oncology Exploratory Development Team at Bristol Meyers Squibb and held various leadership roles in early and late-stage clinical development of the oncology portfolio after he joined in 2005. Dr. Berman was an attending pathologist at the National Cancer Institute of the National Institute of Health. A graduate of Massachusetts Institute of Technology, David earned his Ph.D. in the laboratory of Dr. Alfred Gilman at the University of Texas Southwestern Graduate School and his M.D. from the University of Texas Southwestern Medical School. He completed his residency in anatomic pathology at the National Cancer Institute and was pathology fellow at The Johns Hopkins Hospital.  

Research Interest

anatomic pathology